Medical application of pseudo guaiane sesquiterpene derivative
By developing pseudoguaeros sesquiterpene derivatives, especially marin extracted from pyropodosum plants, as an NLRP3 inflammasome inhibitor, the problem of insufficient activity of existing NLRP3 inhibitors was solved, and the problem of insufficient activity of existing NLRP3 inhibitors was achieved. Effective inhibition of NLRP3 inflammasomes and significant therapeutic effects of inflammatory diseases.
Patent Information
- Application Number
- CN202411325395.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-10-31
- Filing Date
- 2024-09-23
- Publication Date
- 2024-11-12
AI Technical Summary
The existing NLRP3 inhibitors have insufficient structure and activity, especially the natural products have weak activity and high toxicity, making it difficult to effectively inhibit the overactivation of NLRP3 inflammasomes, resulting in poor efficacy in treating inflammatory diseases.
Develop a pseudoguaeros sesquiterpene derivative or a pharmaceutically acceptable salt thereof, especially the genus Borneen (Big) extracted from the genus Aphrodisiac, as an inhibitor of NLRP3 inflammasome activation, using for the treatment of related diseases. Its anti-inflammatory and anti-inflammatory efficacy in the body is improved through specific extraction and preparation methods.
At very low doses, genus ceramino significantly inhibits the activation of NLRP3 inflammasomes, improves acute lung injury, sepsis, asthma, acute gastritis, acute kidney injury and atopic dermatitis, and has better results than previous research results. Potential clinical therapeutic value.
Smart Images

Figure CN118924739A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to small molecule drug technology, in particular to a class of pseudoguaiacyl sesquiterpene derivatives and uses thereof. Background Art
[0002] Inflammasomes are multiprotein complexes that recognize PAMPs (pathogen-associated pattern molecules) and / or DAMPs (damage-associated pattern molecules) in innate immune cells and are an important component of the innate immune response [Front Immunol, 2019; 10: 2538. ]. Among them, NLRP3 inflammasomes are the most important members of inflammasomes because they can recognize multiple stimulatory factors such as nigericin, uric acid crystals, cholesterol crystals and exogenous ATP [Cell, 2016; 165: 792-800. ]. The classic NLRP3 inflammasome activation pathway is to activate the NF-κB pathway after being stimulated by exogenous or endogenous danger signals, upregulating the protein expression of NLRP3, pro-IL-1β and pro-IL-18; then the receptor protein NLRP3 recognizes the second signal such as PAMPs, DAMPs or intracellular stress molecules, recruits the adaptor protein ASC, and then regulates the activity of caspase-1, promotes the secretion and release of inflammatory factors IL-1β and IL-18 and cell pyroptosis, triggers a series of inflammatory cascade reactions, and promotes the occurrence and development of inflammation [NatRev Drug Discov, 2018; 17: 588-606. ].
[0003] NLRP3 is closely related to the occurrence and development of a variety of sterile inflammation and infectious inflammation. Studies have found that the NLRP3 gene is associated with susceptibility to ulcerative colitis (UC), and there is overactivation of NLRP3 inflammasomes in clinical patients [Mucosal Immunol, 2019; 12: 1150-1163. ]. In infectious inflammation such as viral pneumonia, the activation of NLRP3 inflammasomes can be used as a biomarker for the severity of viral pneumonia, clinical efficacy, and therapeutic targets [Nat Rev Immunol, 2021; 94-703; J Exp Med, 2021; 218: e20201707; Nat Commun, 2021; 12: 4664. 】 Overactivation of NLRP3 inflammasomes is present in acute respiratory distress syndrome (ARDS) caused by different types of viral infection of the lungs, and the use of its inhibitors can significantly improve the survival rate of sick mice [J Immunol, 2016; 197: 2421-2433; Immunity, 2021; 54: 1463-1477. 】. In addition, NLRP3 is also involved in the occurrence and development of uncontrollable inflammation such as familial periodic autoinflammatory response, type 2 diabetes, Alzheimer's disease, osteoarthritis, gout, and atherosclerosis [Nat Med, 2015; 21: 248-255; J Clin Invest, 2020; 130: 1961-1976; Cell Metab, 2020; 31: 580-591; Circ Res, 2018; 122: 1722-1740; J Hepatol, 2017; 66: 1037-1046; Autophagy, 2019; 15: 1860-1881; Brain, 2020; 143: 1414-1430; J Clin Invest, 2018; 128: 1793-1806; Nat Commun, 2020; 11: 4243; Arthritis Rheumatol, 2020; 72: 1192-1202. 】. Given that NLRP3 inflammasome is crucial for immune regulation, targeted inhibition of NLRP3 is expected to treat uncontrolled inflammation.
[0004] Given the important role of NLRP3 in inflammatory diseases, the development of NLRP3 inhibitors for the prevention and treatment of inflammatory diseases is of great significance. The development of NLRP3 inhibitors has received widespread attention in the medical community, but no NLRP3 inhibitors are currently on the market. MCC950 is the most studied NLRP3 inhibitor. This compound is a selective NLRP3 inhibitor, but due to its own structural limitations, the derivatives after structural modification generally have a large molecular weight and poor drugability. Due to liver toxicity, MCC950 has been terminated in a Phase II clinical trial for rheumatoid arthritis. The second largest category of NLRP3 inhibitors is mainly natural products such as curcumin, parthenolide, triptolide, andrographolide, and oridonin, but these compounds are generally weak in activity, and their inhibitory activity on NLRP3 inflammasomes is at the micromolar level; in the mouse in vivo inflammation model, an oral dose of 10-100 mg / kg is required to be effective. Therefore, there is still great potential to discover low-toxic and efficient NLRP3 inhibitors from natural products.
[0005] There are about 100 species of Inula in the Asteraceae family, among which Hubei Inula (I.hupehensis) and Helianthus-aquaticae CYWu ex Ling, which are endemic to my country, are used as substitutes for Inula or anti-tumor medicinal plants in their unique production areas. For example, Hubei Inula is produced in Hubei and Sichuan, and is used as Inula in Hubei Province; Inula-aquaticae CYWu ex Ling is produced in Sichuan and Yunnan, and its inflorescence or whole plant is used for colds, headaches, coughs, bronchitis, vomiting, etc., and its roots are used for gingivitis, oral ulcers, and tracheitis. Hubei / Shui Chaoyang Inula japonica is rich in sesquiterpene lactone components. The compounds reported to be isolated include aromaticin, 8-epi-helenalin, bigelovin, 2,3-dihydroaromaticin, carpesiolin, ergolide, etc. Among them, the content of bigelovin and didehydrocarpesiolin is the highest (total > 0.3%).
[0006]
[0007] The anti-inflammatory and anti-tumor effects of Inula japonica have been reported in many papers, among which sesquiterpene lactone components are its main material basis. Among them, the representative component Helenalin (Hel) is considered to be an inhibitor of NF-κB or C / EBPβ, which mainly exerts anti-tumor effects by promoting apoptosis of tumor cells. The effective dose in inhibiting the proliferation of solid tumor cells is at the micromolar level [Cancer Res, 2001; 61: 5817-5823; Cancer Lett, 2022; 530: 170-180; BiomedPharmacother, 2019; 119: 109435; ActaPharmacol Sin, 2015; 36: 507-516; Eur J MedChem, 2013; 59: 243-252; Phytother Res, 2009; 23(6): 885-891; Biochem Pharmacol, 2018; 150: 191-201. ]. In addition, the anti-inflammatory effects of Hel and Big have been reported in many papers, and most of them are concentrated in in vitro experiments. They inhibit the activation of NF-κB and thus inhibit the production of cyclooxygenase COX-2 and nitric oxide synthase iNOS. The effective dose in the cell model is also at the micromolar level [Cell Death Dis, 2017; 8: e271; Arch Pharm Res, 2002; 25: 151-153; J Ethnopharmacol, 2009; 123: 250-256; Life Sci, 2013; 93: 847-854; J Biol Chem, 2016; 291: 26098-26108. ]. In an animal model of acute lung injury, the literature reports that its structural analogue Erg can alleviate LPS-induced acute lung injury in mice when administered orally at 10 mg / kg / d [Int immunopharmacol, 2023; 120: 1110292. ]. Currently, there is no literature reporting that the extract of Inula japonica chinensis is used to prevent and treat colitis, nephritis, sepsis, pneumonia, asthma, atopic dermatitis, etc. Summary of the invention
[0008] Purpose of the invention: The present invention provides a pseudoguaiacyl sesquiterpene derivative or a pharmaceutically acceptable salt thereof as an inhibitor of NLRP3 inflammasome activation in the preparation of a drug for treating NLRP3 inflammasome-related diseases.
[0009] The present invention also provides use of an effective part of an extract of a plant of the genus Inula in preparing a medicine for treating NLRP3 inflammasome-related diseases.
[0010] Technical solution: In order to achieve the above-mentioned object, the present invention provides a pseudoguaiacyl sesquiterpene derivative or a pharmaceutically acceptable salt thereof as shown in the following formula I, which is used as an inhibitor of NLRP3 inflammasome activation in the preparation of a drug for treating NLRP3 inflammasome-related diseases:
[0011]
[0012] Where:
[0013] R1 and R2 together form a double bond;
[0014] or R1 is hydrogen or deuterium, R2 is and pharmaceutically acceptable salts thereof formed with inorganic or organic acids, including hydrochloride and fumaric acid, wherein R4 and R5 are independently selected from hydrogen or C1-C3 alkyl;
[0015] R3 is H or acyl.
[0016] Wherein, the pseudoguaiacyl sesquiterpene derivative or a pharmaceutically acceptable salt thereof is selected from any one of the following compounds:
[0017]
[0018]
[0019] Among them, the use of the method in the preparation of a drug for treating NLRP3 inflammasome-related diseases includes immune diseases, autoimmune diseases, kidney system-related diseases, gastrointestinal tract-related diseases, respiratory diseases, infectious diseases, and skin diseases.
[0020] Furthermore, the respiratory diseases include acute lung injury, asthma, asbestosis, and silicosis.
[0021] Furthermore, the kidney system related diseases include chronic kidney disease, oxalate nephropathy and diabetic nephropathy.
[0022] Furthermore, the gastrointestinal tract related diseases include inflammatory bowel disease and gastritis, and the infectious diseases include inflammatory cytokine storm and sepsis caused by bacterial and viral infections.
[0023] Furthermore, the skin disease includes atopic dermatitis.
[0024] The effective part of the Inula plant extract of the present invention includes caerulein in the compound shown in formula I, and the mass percentage of caerulein in the effective part is 10%-90%.
[0025] The invention discloses a use of the effective part of the Inula plant extract in the preparation of a medicine for treating NLRP3 inflammasome-related diseases.
[0026] The pharmaceutical composition of the present invention comprises any one of the pseudoguaiacyl sesquiterpene derivatives of formula I or a pharmaceutically acceptable salt thereof, or an effective part of the Inula plant extract, and a pharmaceutically acceptable carrier.
[0027] The effective part of the extract of the genus Inula is the effective part of the extract containing chaerulein in the compound shown in formula I, and its content accounts for 10%-90% by mass of the effective part.
[0028] Furthermore, the pharmaceutical composition is used in the preparation of a drug for treating NLRP3 inflammasome-related diseases.
[0029] The present invention found that jinjusu (Big) has a strong activity in inhibiting the activation of NLRP3 inflammasomes, among which the IC of IL-1β inhibition rate of Big in mouse bone marrow-derived macrophages BMDM is 50 The IC value of IL-1β inhibition in human peripheral blood mononuclear cells (PBMCs) is 46 nM. 50 The IC of IL-1β inhibition in human monocytic THP-1 cells is 38 nM. 50 The content of Big in the 1mg / kg / day and the 2mg / kg / day of Big was 397nM. In the present invention, intraperitoneal injection of Big prevented sepsis in mice, and showed strong anti-acute lung injury (ALI) and anti-sepsis activities at a dose of 0.01mg / kg / d; while oral administration of Big showed strong anti-ALI, anti-sepsis and anti-asthma activities at a dose of 0.1mg / kg / d. In addition, Big also showed the same anti-inflammatory activity in DSS-induced acute colitis and hydrochloric acid-induced acute gastritis, and also had good therapeutic effects on folic acid-induced acute kidney injury and atopic dermatitis. In addition, after oral administration of SHA-3, an effective part of the extract of the genus Inula, at a dose of 0.1 mg / kg / d, the present invention also showed good therapeutic effects in ALI and acute colitis models. At a dose of 1 mg / kg, SHA-3 significantly reduced DSS-induced colitis and inhibited the shortening of the colon length of mice. After applying 0.1% and 1% compound Big ointment, the ear damage of atopic dermatitis (AD) mice was significantly alleviated.
[0030] NLRP3 inflammasome is the central hub of the innate immune response, mediates the secretion of pro-inflammatory factors, recognizes a variety of stimulatory factors, and plays an important role in inflammation. The present invention found through in vitro experiments that chamaecyparin in Inula japonica has a strong inhibitory effect on NLRP3 inflammasomes, and then found that it also has strong anti-inflammatory activity in NLRP3-related in vivo experiments. The present invention proposes for the first time a pseudoguaiacyl sesquiterpene derivative shown in formula I or a pharmaceutically acceptable salt thereof as an inhibitor of NLRP3 inflammasome activation, which can be used to prepare drugs for treating NLRP3 inflammasome-related diseases, and the effect is significant.
[0031] The present invention extracts the effective part of the Inula plant extract by a specific method. After analysis, the extract contains a certain dose of chamaecyparin. The effective part of the Inula plant extract extracted by the specific method of the present invention can also be used as an NLRP3 inflammasome activation inhibitor in the preparation of drugs for treating NLRP3 inflammasome-related diseases, such as acute lung injury, sepsis, asthma, acute colitis, acute gastritis, acute kidney injury, atopic dermatitis, etc.
[0032] The present invention has found that the effective ingredient chamaemonin and its derivatives in Inula japonica have good therapeutic effects on sepsis, acute pneumonia, asthma, colitis, gastritis, kidney injury and atopic dermatitis at extremely low dosages (the effective dosage for intraperitoneal injection is 0.01 mg / kg / d. The effective dosage for oral gavage is 0.1 mg / kg / d), which is significantly enhanced than the effective dosage of 10 mg / kg / d of chamaemonin analog Erg reported in the literature. Therefore, the present invention has a significant effect.
[0033] Beneficial effects: The present application provides a novel use of pseudoguaiacyl sesquiterpene derivatives or pharmaceutically acceptable salts thereof, or effective parts of extracts of the genus Inula in the preparation of drugs for treating NLRP3 inflammasome-related diseases. Experimental verification shows that the compounds of the present application can strongly inhibit the activation of NLRP3 inflammasomes, significantly improve acute lung injury in mice, reduce inflammation in sepsis and asthma models, show good therapeutic effects on acute gastritis and acute kidney injury, significantly inhibit the onset of acute colitis and atopic dermatitis in mice, and the effect is significantly better than the positive control, and has potential pharmaceutical applications for anti-acute lung injury, anti-sepsis, anti-asthma, anti-ulcerative colitis, treatment of gastritis and kidney injury, and atopic dermatitis.
[0034] At the same time, the effective part of the Inula plant extract extracted by the specific method of the present invention can also effectively inhibit the activation of NLRP3 inflammasome, and can be used for the treatment or auxiliary treatment of immune diseases, autoimmune diseases, kidney system-related diseases, gastrointestinal tract-related diseases, respiratory diseases, and infectious diseases. DETAILED DESCRIPTION
[0035] In order to more clearly illustrate the technical solution of the present invention, it is described in detail below in conjunction with specific embodiments.
[0036] The Shuichaoyang Inula flower raw materials used in the process of the present invention are collected from Mianyang, Sichuan, and the Hubei Inula flower raw materials are collected from Enshi, Hubei.
[0037] Example 1
[0038] Preparation of SHA-1, an effective fraction of the extract of the genus Inula:
[0039] Take 100g of dried flowers of Inula japonica (Shuichaoyang or Hubei Inula japonica, Shuichaoyang Inula japonica is taken as an example), put them in a 2L round-bottom flask, add 1L of petroleum ether, heat to 90°C, reflux extraction four times, each time for 2 hours, combine the extracts, recover the solvent under reduced pressure to obtain 4.19g of extract, add five times the amount of anhydrous ethanol, heat until completely dissolved, cool naturally and then centrifuge and filter, and concentrate the filtrate to dryness under reduced pressure to obtain 3.31g of extract SHA-1, with a yield of 3.31%. HPLC content analysis shows that the content of Big in the extract is 12.8%.
[0040] Example 2
[0041] Preparation of SHA-2, an effective fraction of the extract of the genus Inula:
[0042] Take 200g of the dried whole herb of Inula japonica (Shuichaoyang or Hubei Inula japonica, Shuichaoyang Inula japonica is taken as an example), put it in a 5L round-bottom flask, add 2L of petroleum ether, heat to 90°C, reflux extraction four times, each time for 2 hours, combine the extracts, reduce pressure and recover the solvent to obtain 8.21g of extract, add five times the amount of anhydrous ethanol, heat until completely dissolved, cool naturally and then centrifuge and filter, reduce pressure and concentrate the filtrate to dryness to obtain 6.32g of extract SHA-2, with a yield of 3.16%. HPLC content analysis shows that the content of Big in the extract is 22.0%.
[0043] Example 3
[0044] Preparation of SHA-3, an effective fraction of the extract of the genus Inula:
[0045] Take 100g of dried flowers of Inula japonica (Shui Chaoyang or Hubei Inula japonica, Shui Chaoyang Inula japonica is taken as an example), put them in a 2L round-bottom flask, add 1L of petroleum ether, heat to 90°C, reflux extraction four times, each time for 2 hours, combine the extracts, and reduce pressure to recover the solvent to obtain 4.19g of extract, take the petroleum ether extract, add 20 times the volume of 60% ethanol, heat to 80°C and reflux extraction twice, pour out the supernatant, filter, and reduce pressure to recover the solvent to obtain 1.68g of alcohol-water treated extract, add five times the amount of anhydrous ethanol to the alcohol-water treated extract, heat until completely dissolved, cool naturally, and filter to obtain 5.6mg of coarse crystal SHA-314, with a yield of 0.14%. According to HPLC content analysis, the content of chamomile (Big) in the extract is 23.5%.
[0046] Example 4
[0047] Preparation of SHA-4, an effective fraction of the extract of the genus Inula:
[0048] Take 200g of the dried whole herb of Inula japonica (Shui Chaoyang or Hubei Inula japonica, Shui Chaoyang Inula japonica is taken as an example), place it in a 5L round-bottom flask, add 2L of petroleum ether, heat to 90°C, reflux extraction four times, each time for 2 hours, combine the extracts, and reduce pressure to recover the solvent to obtain 8.20g of extract, take the petroleum ether extract, add 20 times the volume of 60% ethanol, heat to 80°C and reflux extraction twice, pour out the supernatant, filter, and reduce pressure to recover the solvent to obtain 3.01g of alcohol-water treated extract, add five times the amount of anhydrous ethanol to the alcohol-water treated extract, heat until completely dissolved, cool naturally, and filter to obtain 4.2mg of coarse crystal SHA-444, with a yield of 0.22%. According to HPLC content analysis, the content of chamomile (Big) in the extract is 48.6%.
[0049] Example 5
[0050] Preparation of SHA-5, an effective fraction of the extract of the genus Inula:
[0051] Take 100g of dried flowers of Inula japonica (Shuichaoyang or Hubei Inula japonica, Shuichaoyang Inula japonica as an example), place in a 2L round-bottom flask, add 1L of 80% ethanol, heat to 80℃ and reflux for extraction three times, each time for 2 hours, pour out the supernatant, filter, cool to room temperature, prepare the filtrate into 30% ethanol solution, and slowly add 2 times of D101 macroporous resin. After adsorption, gradient elution with 30%-70% ethanol is carried out in sequence, and 40%-50% of the parts are enriched to obtain 294.23mg of alcohol-water treated extract; add five times of anhydrous ethanol, heat until completely dissolved, centrifuge and filter after natural cooling, concentrate the filtrate to dryness under reduced pressure, and the extract is isocratically eluted by reverse phase HPLC preparation column (methanol: water = 1: 1) to obtain 3.56mg of extract SHA-5, with a yield of 0.07%. According to HPLC content analysis, the content of chamomile (Big) in the extract is 87.3%.
[0052] Example 6
[0053] Preparation of SHA-6, an effective fraction of the extract of the genus Inula:
[0054] Take 200g of the dried whole herb of Inula japonica (Shuichaoyang or Hubei Inula japonica, Shuichaoyang Inula japonica is taken as an example), place it in a 5L round-bottom flask, add 2L of 80% ethanol, heat to 80℃ and reflux for extraction three times, each time for 2 hours, pour out the supernatant, filter, cool to room temperature, prepare the filtrate into a 30% ethanol solution, and slowly add 2 times the amount of D101 macroporous resin. After adsorption, 30%-70% ethanol gradient elution is carried out in sequence, and 40%-50% of the parts are enriched to obtain 596.62mg of alcohol-water treated extract; add five times the amount of anhydrous ethanol, heat until completely dissolved, cool naturally and filter by centrifugation, concentrate the filtrate to dryness under reduced pressure, and the extract is eluted isocratically by reverse phase HPLC preparation column (methanol: water = 1: 1) to obtain 1.88mg of extract SHA-620, with a yield of 0.10%. According to HPLC content analysis, the content of chamomile (Big) in the extract is 92.4%.
[0055] The extracts of Inula japonica SHA1-6 obtained in Examples 1-6 were separated by a reverse phase HPLC preparative column and recrystallized to obtain Big and 8-epi-helenalin. C18, 30x 100mm, 10μm), 30%-50% methanol-water gradient elution, HPLC tracking detection, 30% methanol fraction main component is 8-epihelenalin (used for the subsequent examples to verify the compound I-4), methanol-water recrystallization to obtain 83mg white crystals (purity>96%), 50% methanol fraction main component is Big (used for the subsequent examples to verify the compound I-1), methanol-water recrystallization to obtain 229mg white crystals (purity>98%). Big: 1 H NMR (500MHz, CD3OD) δ3.02(m,1H),7.70(dd,J=5.8,1.2Hz,1H),6.09(dd,J=5.9,2.7Hz,1H),5.59(d,J=7.5Hz,1H),3.07(m,1H),4.61(dd,J= 12.9, 2.7Hz, 1H), 2.58 (dt, J = 16.6, 3.6Hz, 1H), 2.58 (dd, J = 12.1, 24.7Hz, 1H), 2.05 (m, 1H), 1.27 (d, J = 6.5Hz, 3H), 1.19 (s, 3H), 1.94 (s, 3H). ESI-MS(m / z):[M+H] +=305.1(calcd:305.1);8-epi-helenalin: 1 HNMR(500MHz,CD3OD)δ7.79(dd,J=5.9and 2.0Hz 1H),6.26(d,J=3.6Hz,1H),6.16(dd,J=6.0,2.8Hz,1H),6.10-5.99(m.1H),4.55(ddd,J=11.8,10.2,d 3.0Hz,1H),4.17(dd,J=8.3,2.2Hz,1H),3.01(dt,J=10.8,2.4Hz,1H),2.93(ddt,J=10.2,8.2,3.4Hz,1H)2. 54(ddd,J=13.1,4.6,2.9Hz,1H),2.26-2.00(m,2H),1.57-1.47(m,1H),1.29(d,J=6.6Hz,3H),1.20(s,3H). ESI-MS(m / z):[M+H] + =263.1(calcd:263.1)
[0056] The methods for preparing Big and 8-epi-helenalin in Examples 2-6 are the same as those in Example 1.
[0057] The above experiments effectively prove that the effective part of the extract prepared by the present invention contains Big and 8-epi-helenalin.
[0058] TLC conditions test:
[0059] Silica gel G plate; developing agent: petroleum ether-ethyl acetate (2:1); color developer: vanillin concentrated sulfuric acid color developer.
[0060] The extracts SHA1-6 of Inula japonica with different Big contents were developed under TLC conditions and developed with vanillin and concentrated sulfuric acid as a color developer, and yellow spots appeared. The Rf value of Big was 0.33.
[0061] Chromatographic analysis conditions:
[0062] Chromatographic column: Agilent Zorbax SB-C184.6*250mm; mobile phase: methanol: water = 45:55; flow rate: 0.8mL / min; detection wavelength: 210nm; column temperature: 30℃; injection volume: 10μL; analysis time 50min, retention time of Big is 18.7min. Accurately weigh 10.68mg of compound Big (prepared according to the above example, purity>98%) as the reference substance, dissolve in methanol, dilute and dilute to 10mL volumetric flask, respectively as the reference substance stock solution, draw the standard curve. Measure the peak area at a wavelength of 210nm, draw the standard curve with the peak area value as the ordinate and the solution concentration as the abscissa, and get the Big regression equation: Y=25813846.7440X+385110.1250 (R=0.9991), the linear range is 0.015~12mg / mL.
[0063] Chromatographic analysis results:
[0064] Through the above experiments and chromatographic analysis results, it was found that the Big contents in the samples of Examples 1-6 were 12.8%, 22.0%, 23.5%, 48.6%, 87.3% and 92.4%, respectively.
[0065] Example 7
[0066] Preparation method of compound I-2
[0067]
[0068] Add 134 mg (1.64 mmol) of dimethylamine hydrochloride, 455 mg (3.29 mmol) of anhydrous potassium carbonate, and 2 mL of dichloromethane to the reaction flask, stir at room temperature for 20 minutes, then add 50 mg (0.16 mmol) of compound I-1 (Big), stir at room temperature for 4 hours. After TLC (petroleum ether: ethyl acetate = 2: 1) confirms that the reaction is complete, add 10 mL of water to quench, extract with ethyl acetate, wash with saturated sodium chloride solution, dry with anhydrous sodium sulfate, and remove the solvent under reduced pressure to obtain an oil.
[0069] The desiccant was filtered off and the mixture was dried under reduced pressure to give a viscous substance. 1 mL of ethyl acetate was added and the mixture was cooled to 0°C with stirring in an ice bath. 0.5 mL of EA·HCl was slowly added to precipitate a white solid. The solid was filtered and washed with ethyl acetate to give 36 mg of compound I-2 with a yield of 63%. 1H NMR (500MHz, CD3OD) δ7.93 (dd, J=6.0, 2.0Hz, 1H), 6.10 (dd, J=6.0, 2.8Hz, 1H), 5.46 (dd, J=7.6, 2.2Hz ,1H),5.00(td,J=10.9,2.7Hz,1H),3.64-3.48(m,2H),3.06(dt,J=10.7,2.7Hz,1H),3.00(dd,J=8.1,2 .9Hz),2.96(s,6H),2.59(dq,J=10.7,5.7,3.4Hz,1H),2.51(ddd,J=12.9,4.6,3.0Hz,1H),2.13(tdd,J =11.2, 6.6, 4.7Hz, 1H), 1.99 (s, 3H), 1.58 (qd, J = 12.1, 4.2Hz, 1H), 1.30 (d, J = 6.5Hz, 3H), 1.26 (s, 3H). ESI-MS(m / z):[M+H] + =350.1(calcd:350.1).
[0070] Example 8
[0071] Preparation method of compound I-3
[0072]
[0073] Add 134 mg (1.64 mmol) of dimethylamine hydrochloride, 455 mg (3.29 mmol) of anhydrous potassium carbonate, and 2 mL of dichloromethane to the reaction flask, stir at room temperature for 20 minutes, then add 50 mg (0.16 mmol) of compound I-1 (Big), stir at room temperature for 4 hours. After TLC (petroleum ether: ethyl acetate = 2: 1) confirms that the reaction is complete, add 10 mL of water to quench, extract with ethyl acetate, wash with saturated sodium chloride solution, dry with anhydrous sodium sulfate, and remove the solvent under reduced pressure to obtain an oil.
[0074] To the oil was added 1 mL of methanol, and 19 mg (0.17 mmol) of fumaric acid (dissolved in methanol) was slowly added at room temperature. After stirring for 30 minutes, the solvent was removed under reduced pressure to obtain a white solid which was slurried with ethyl acetate and filtered to obtain 353 mg of compound I-3, with a yield of 93%. 1HNMR(500MHz,CD3OD)δ7.92(dd,J=6.0,2.0H,1H),6.13-6.07(m,1H),5.45(d,J=7.6Hz,1H ),5.02-4.93(m,1H),3.52(dddJ=11.6,10.3,3.4Hz,1H),3.44-3.37(m,1H),2.95(dd,J=1 3.1,3.5Hz,1H),2.89(d,J=11.0Hz,6H),2.71(s,1H),2.62-2.48(m,2H),2.18-2.06(m,1H ),1.98(s,3H),1.65-1.52(m,1H),1.29(d,J=6.5Hz,3H),1.26(s,3H).ESI-MS(m / z):[M+H] + =350.1(calcd:350.1).
[0075] Example 9
[0076] Preparation method of compound I-5
[0077]
[0078] The preparation method of compound I-5 is the same as that of compound I-2. Add 156 mg (1.9 mmol) of dimethylamine hydrochloride, 528 mg (3.8 mmol) of anhydrous potassium carbonate, and 2 mL of dichloromethane to the reaction bottle, stir at room temperature for 20 minutes, then add 50 mg (0.19 mmol) of compound I-4 (8-epi-helenalin), stir at room temperature for 4 hours. After TLC (petroleum ether: ethyl acetate = 2: 1) confirms that the reaction is complete, add 10 mL of water to quench, extract with ethyl acetate, wash with saturated sodium chloride solution, dry with anhydrous sodium sulfate, and remove the solvent under reduced pressure to obtain an oil.
[0079] The desiccant was filtered off and the mixture was dried under reduced pressure to give a viscous substance. 1 mL of ethyl acetate was added and the mixture was cooled to 0°C with stirring in an ice bath. 0.5 mL of EA·HCl was slowly added to precipitate a white solid. The solid was filtered and washed with ethyl acetate to give 50 mg of compound I-5 with a yield of 85%. 1H NMR (500MHz, CD3OD) δ7.93(dd,J=6.01,9Hz,1H),6.12(dd,J=6.0,2.8Hz,1H),4.85(d ,J=4.9Hz,1H),4.12(d,J=8.3Hz,1H),3.59-3.55(m,1H),3.53-3.46(m,2H),3.36-3. 34(m,1H),3.04-3.01(m,1H),3.00(s,6H),2.52-2.47(m,1H),2.46-2.40(m,1H),2.1 1(qt,J=11.8,6.4Hz,1H),1.50(qt,J=12.1Hz,1H),1.28(d,J=6.5Hz,3H),1.21(s,3H). ESI-MS(m / z):[M+H] + =308.1(calcd:308.1).
[0080] Example 10
[0081] Preparation method of compound I-6
[0082]
[0083] The preparation method of compound I-6 is the same as that of compound I-3. Add 156 mg (1.9 mmol) of dimethylamine hydrochloride, 528 mg (3.8 mmol) of anhydrous potassium carbonate, and 2 mL of dichloromethane to the reaction bottle, stir at room temperature for 20 minutes, then add 50 mg (0.19 mmol) of compound I-4 (8-epi-helenalin), stir at room temperature for 4 hours. After TLC (petroleum ether: ethyl acetate = 2: 1) confirms that the reaction is complete, add 10 mL of water to quench, extract with ethyl acetate, wash with saturated sodium chloride solution, dry with anhydrous sodium sulfate, and remove the solvent under reduced pressure to obtain an oil.
[0084] 1 mL of methanol was added to the oil, and 22 mg (0.19 mmol) of fumaric acid (dissolved in methanol) was slowly added at room temperature. After stirring for 30 minutes, the solvent was removed under reduced pressure to obtain a white solid which was slurried with ethyl acetate and filtered to obtain 52 mg of compound I-6, with a yield of 90%. 1HNMR (500MHz, CD3OD) δ7.93 (dd,J=6.1.1.9Hz.1H), 6.12 (dd,J=6.0,2.9Hz,1H), 4. 85(s,1H),4.12(d,J=8.3Hz,1H),3.62-3.55(m,1H),3.54-3.47(m,2H),3.01(t,J= 2.4Hz,1H),3.00(s,6H),2.72(s,1H),2.47(dddd,J=26.7,1.3,6.5,4.4Hz,2H),2. 18-2.05(m,1H),1.50(dt,J=13.0,11.8Hz,1H),1.28(d,J=6.6Hz,3H),1.21(s,3H). ESI-MS(m / z):[M+H] + =308.1(calcd:308.1).
[0085] Embodiment 11
[0086] Rat plasma conversion experiment of prodrug compounds I-2, I-3, I-5, and I-6
[0087] Sample preparation: 6 mg of compounds I-2, I-3, I-5, and I-6 prepared in Examples 7 to 10 of the present invention were respectively dissolved in 10 mL of deionized water and dissolved with ultrasound assistance.
[0088] Experimental method: Take 400 μL of rat blank plasma (n=3), add an equal volume of 300 μg / mL compound I-2, I-3, I-5, I-6 aqueous solution, incubate in a constant temperature oscillator at 60 r / min and 37°C, take 50 μL of drug-containing plasma (plasma containing compounds I-2, I-3, I-5, I-6) in 150 μL MeOH at different time periods of 1, 5, 10, 15, 30, 45, 60, 90 min, 2, 4, 6, 8, 10, 12, and 24 h, vortex for 3 min, centrifuge at 4°C and 14000 rpm for 10 min, and take the supernatant for HPLC analysis.
[0089] Chromatographic analysis conditions:
[0090] Chromatographic column: Agilent Zorbax SB-C184.6*250mm; mobile phase: methanol / water gradient elution (0-35min, 10%-90% methanol); flow rate: 0.8mL / min; detection wavelength: 210nm; column temperature: 30℃; injection volume: 40μL; analysis time 35min.
[0091] Table 1. Conversion of prodrugs I-2, I-3, I-5, and I-6 in rat plasma
[0092]
[0093]
[0094] By comparing the chromatographic peaks with the prototype compounds and quantitative determination, the results are shown in Table 1. Prodrug compounds I-2 and I-3 (300 μg / mL) can be converted into prototype compound I-1 (complete conversion within 8 hours) in rat plasma, and prodrug compounds I-5 and I-6 (300 μg / mL) can also be converted into prototype compound I-4 in rat plasma (conversion rates within 24 hours are 86.01% and 88.20%). The efficiency of compound I-2 and I-3 conversion into I-1 is slightly higher than that of compound I-4 prodrug (I-5, I-6), and the fumarate I-3 conversion efficiency is the highest (conversion rate is 54.19% at 1 hour). At the same time, subsequent experiments also effectively proved that compound I-1 and compound I-4 can inhibit the activity of NLRP3 inflammasome activation, so its prodrug compounds I-2, I-3, I-5, and I-6 can effectively inhibit the activity of NLRP3 inflammasome activation.
[0095] Example 12
[0096] Preparation method of SHA-1-6 prodrugs of effective parts of Inula plant extract
[0097] The method for preparing the prodrugs of the effective fraction SHA-1 to 6 of the Inula plant extract is the same as the method for preparing compound I-2 in Example 7 of the present invention, except that compound I-1 is replaced by the effective fraction SHA-1 to 6 prepared in Example 1-6 of the present invention.
[0098] Embodiment 13
[0099] Evaluation of the inhibitory activity of Big(I-1), 8-epi-helenalin(I-4) and SHA-1~6 on NLRP3 inflammasome activation
[0100] Experimental reagents
[0101] The I-1, I-4, and SHA-1 to 6 drugs used were prepared according to the above Examples 1-6. LPS was purchased from Sigma, USA; MCC950 was purchased from Shanghai Taoshu Biotechnology Co., Ltd.; ATP was purchased from Aladdin Biochemical Technology Co., Ltd.; ELISA kit was purchased from Dakoway Biotechnology Co., Ltd.; RPMI-1640 culture medium was purchased from Gibco; and fetal bovine serum was purchased from BIbiological industries.
[0102] Experimental methods
[0103] Mouse bone marrow-derived macrophages BMDMs were used to establish an LPS+ATP-induced NLRP3 activation model (He, H. et al. Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity. Nat Commun 9, 2550 (2018).), and the secretion of inflammatory factor IL-1β was detected by ELISA. The effects of compounds Big and SHA-1 to 6 on NLRP3 inflammasome activation were detected (Table 2-3).
[0104] All data are presented as means±SEM, and the statistical differences among the groups were analyzed using one-way ANONA and t-test in SPSS software. P values less than 0.05 were considered to be significantly different.
[0105] Table 2. Inhibition rate of compounds on IL-1β in cell supernatant
[0106]
[0107] Table 3. Expression of IL-1β in cell supernatant
[0108] Compound Name <![CDATA[IC 50 -IL-1β(nM)(BMDMs)]]> <![CDATA[IC 50 -IL-1β(nM)(THP-1)]]> I-1 46 397 I-4 539 765
[0109] As shown in Table 2, among the effective parts of Inula japonica (SHA-1 to 6), as the content of Big increases, its activity in inhibiting IL-1β becomes stronger. As shown in Table 3, in vitro in mouse-derived BMDM cells and human THP-1 cells, Big (I-1) and I-4 both showed inhibitory effects on IL-1β produced by NLRP3 inflammasome activation, among which Big had a stronger inhibitory effect. In BMDM cells, the IC value of I-4 in inhibiting IL-1β produced by NLRP3 inflammasome activation was 50 The IC of I-4 in inhibiting IL-1β produced by NLRP3 inflammasome activation in human THP-1 cells was 539nM, and Big could reach 46nM. 50 is 765nM, and Big can reach 397nM.
[0110] Embodiment 14
[0111] Anti-sepsis testing of compound Big
[0112] Experimental reagents
[0113] The drugs used were prepared according to the above Examples 1-6, code-named Big; LPS was purchased from Sigma, USA; dexamethasone (Dex) was purchased from Sigma, USA; and ELISA kits were purchased from Dakoway Biotech Co., Ltd.
[0114] Experimental animals
[0115] Male C57BL / 6 mice, 6-8 weeks old, weighing 18-20 g, were purchased from Jiangsu Jicui Pharmaceutical Technology Co., Ltd. [Production License No.: SCXK (Su) 2018-0008]. The animals were fed and watered freely and were kept in an environment with a room temperature of 22±2°C and a humidity of 45±10%. After 7 days of adaptive feeding, they were used for subsequent experiments.
[0116] Experimental methods
[0117] Establishment of mouse sepsis model and group-based drug administration
[0118] Intraperitoneal injection of Big to prevent sepsis in mice: Male C57BL / 6J mice, 6-8 weeks old, weighing 18-20g, were randomly divided into a normal group (Normal), a model group (LPS), a Big (concentrations of 0.01 mg / kg, 0.1 mg / kg) group, and a positive control drug dexamethasone (Dex, 5 mg / kg) group according to their weight, with 6 mice in each group. Three days before modeling, Big (0.01 mg / kg, 0.1 mg / kg) and positive drug dexamethasone (Dex, 5 mg / kg) were administered intraperitoneally every day. On the third day, LPS (7.5 mg / kg) was injected intraperitoneally half an hour after administration. Serum was collected 12 hours after LPS administration, and the effect of Big on the expression of inflammatory factors in mouse serum was detected by ELISA (Table 4).
[0119] Intragastric injection of Big to prevent sepsis in mice: Male C57BL / 6J mice, 6-8 weeks old, weighing 18-20g, were randomly divided into a normal group (Normal), a model group (LPS), a Big (concentrations of 0.1 mg / kg, 1 mg / kg) group, and a positive control drug Dex (5 mg / kg) group according to their weight, with 6 mice in each group. Three days before modeling, Big (0.1, 1 mg / kg) was administered by intragastric gavage, and the positive drug dexamethasone (Dex, 5 mg / kg) was administered by intraperitoneal injection. On the third day, LPS (7.5 mg / kg) was injected intraperitoneally half an hour after administration. Serum was collected 12 hours after LPS administration, and the effect of Big on the expression of inflammatory factors in mouse serum was detected by ELISA (Table 5).
[0120] Intraperitoneal injection of Big to treat sepsis in mice: Male C57BL / 6J mice, 6-8 weeks old, weighing 18-20g, were randomly divided into a normal group (Normal), a model group (LPS), a Big (concentrations of 0.01 mg / kg, 0.1 mg / kg) group, and a positive control drug Dex (5 mg / kg) group according to their weight, with 6 mice in each group. LPS (7.5 mg / kg) was injected intraperitoneally, and Big (concentrations of 0.01 mg / kg, 0.1 mg / kg) and Dex (5 mg / kg) were intraperitoneally injected half an hour after modeling. Serum was collected 24 hours after administration, and the effect of Big on the expression of inflammatory factors in mouse serum was detected by ELISA (Table 6).
[0121] Statistics
[0122] All data are presented as means±SEM, and the statistical differences among the groups were analyzed using one-way ANONA and t-test in SPSS software. P values less than 0.05 were considered to be significantly different.
[0123] Effects of intraperitoneal prophylactic administration of Big on sepsis in mice
[0124] As shown in Table 4, compared with the Normal group mice, the serum IL-1β and IL-6 levels of the LPS group mice increased significantly. Intraperitoneal injection of the compound Big (0.01 mg / kg and 0.1 mg / kg) inhibited the increase of IL-1β and IL-6 in the serum of mice in a dose-dependent manner.
[0125] Table 4 Expression of inflammatory factors (IL-1β and IL-6) in the serum of Big mice given preventive intraperitoneal injection
[0126] Group Number IL-1β (pg / mL) IL-6 (pg / mL) Normal 6 30.42±0.76 27.98±1.33 LPS 6 315.80±33.37 27744.00±1595.00 Big (0.01 mg / kg) 6 341.30±57.70 <![CDATA[20141.00±1815.00 * ]]> Big (0.1 mg / kg) 6 <![CDATA[135.20±4.45 *** ]]> <![CDATA[13189.00±5881.00 *** ]]> Dex (5 mg / kg) 6 <![CDATA[44.34±2.21 *** ]]> <![CDATA[1850.00±278.40 *** ]]>
[0127] Note: *p<0.05; **p<0.01; ***p<0.001 (compared with LPS group).
[0128] Effects of preventive administration of Big by intragastric administration on sepsis in mice
[0129] As shown in Table 5, compared with the mice in the Normal group, the IL-1β and IL-6 in the serum of the mice in the LPS group increased significantly. The preventive administration of the compound Big (0.1 mg / kg and 1 mg / kg) by oral gavage inhibited the increase of IL-1β and IL-6 in the serum of mice in a dose-dependent manner, and the activity of Big (1 mg / kg) in inhibiting IL-6 was significantly stronger than that of the positive control Dex.
[0130] Table 5 Expression of inflammatory factors (IL-1β and IL-6) in the serum of Big mice given oral preventive medication
[0131]
[0132]
[0133] Note: *p<0.05; **p<0.01; ***p<0.001 (compared with LPS group).
[0134] Effects of intraperitoneal administration of Big on sepsis in mice
[0135] As shown in Table 6, compared with the Normal group mice, the serum IL-1β and IL-6 in the LPS group mice increased significantly. Intraperitoneal injection of compound Big (0.01 mg / kg and 0.1 mg / kg) dose-dependently inhibited the increase of IL-1β and IL-6 in the serum of mice.
[0136] Table 6 Expression of inflammatory factors (IL-1β and IL-6) in the serum of Big mice treated with intraperitoneal injection
[0137]
[0138] Note: *p<0.05; **p<0.01; ***p<0.001 (compared with LPS group).
[0139] Embodiment 15
[0140] Anti-acute lung injury activity test of compounds Big and SHA-3
[0141] Experimental reagents
[0142] The drugs used were prepared according to the above Examples 1-6, code-named Big; LPS was purchased from Sigma, USA; dexamethasone (Dex) was purchased from Sigma, USA; and ELISA kits were purchased from Dakoway Biotech Co., Ltd.
[0143] Experimental animals
[0144] Male C57BL / 6 mice, 6-8 weeks old, weighing 18-20 g, were purchased from Jiangsu Jicui Pharmaceutical Technology Co., Ltd. [Production License No.: SCXK (Su) 2018-0008]. The animals were fed and watered freely and were kept in an environment with a room temperature of 22±2°C and a humidity of 45±10%. After 7 days of adaptive feeding, they were used for subsequent experiments.
[0145] Experimental methods
[0146] Establishment of acute lung injury model in mice and group-based drug administration
[0147] Intraperitoneal injection of Big for the treatment of acute lung injury: Male C57BL / 6J mice, 6-8 weeks old, weighing 18-20g, were randomly divided into a normal group (Normal), a model group (LPS), a Big (0.01mg / kg, 0.1mg / kg) group, and a positive control drug Dex (5mg / kg) group according to their weight, with 6 mice in each group. LPS (7.5mg / kg) was injected intraperitoneally, and Big (0.01mg / kg, 0.1mg / kg) and Dex (5mg / kg) were injected intraperitoneally half an hour after modeling. Lung tissues were collected 24 hours after administration, and the effect of Big on the expression of inflammatory factors in the lung tissues of mice with acute lung injury was detected by ELISA (Table 7).
[0148] Intragastric injection of SHA-3, an effective part of the extract of Inula japonica, to prevent acute lung injury: Male C57BL / 6J mice, 6-8 weeks old, weighing 18-20g, were randomly divided into a normal group, a model group, a SHA-3 (0.1, 1 mg / kg) group, and a positive control drug Dex (5 mg / kg) group according to their weight, with 6 mice in each group. SHA-3 was administered intragastricly three days before modeling, and the positive drug Dex was administered by intraperitoneal injection. On the third day, LPS (7.5 mg / kg) was injected intraperitoneally half an hour after administration. LPS was administered 12 hours after the administration of LPS, and the lung tissue was collected. The effect of SHA-3 on the expression of inflammatory factors in the lung tissue of mice with acute lung injury was detected by ELISA (Table 8).
[0149] Statistics
[0150] All data are presented as means±SEM, and the statistical differences among the groups were analyzed using one-way ANONA and t-test in SPSS software. P values less than 0.05 were considered to be significantly different.
[0151] Effects of intraperitoneal administration of Big on acute lung injury in mice
[0152] As shown in Table 7, compared with the Normal group mice, the IL-1β and IL-6 in the lung tissue of the LPS group mice increased significantly. Intraperitoneal injection of the compound Big (0.01 mg / kg and 0.1 mg / kg) dose-dependently inhibited the increase of IL-1β and IL-6 in the lung tissue of mice, and the activity of Big (0.1 mg / kg) in inhibiting IL-1β was significantly stronger than that of the positive control Dex.
[0153] Table 7 Expression of inflammatory factors (IL-1β and IL-6) in lung tissue of Big mice treated with intraperitoneal injection
[0154]
[0155] Note: *p<0.05, **p<0.01, ***p<0.001 (compared with LPS group).
[0156] Effects of preventive administration of Big and Erg mixture by intragastric administration on acute lung injury in mice
[0157] As shown in Table 8, compared with the mice in the Normal group, the IL-1β and IL-6 in the lung tissue of the mice in the LPS group increased significantly. The oral administration of SHA-3 (0.1 mg / kg and 1 mg / kg), the effective part of the extract of the genus Inula, inhibited the increase of IL-1β and IL-6 in the lung tissue of mice in a dose-dependent manner, and was significantly stronger than the positive control Dex.
[0158] Table 8 Expression of inflammatory factors (IL-1β and IL-6) in lung tissue of mice given SHA-3 by oral administration
[0159]
[0160]
[0161] *p<0.05; **p<0.01, ***p<0.001 (compared with the LPS group).
[0162] Example 16
[0163] Anti-ulcerative colitis activity test of compounds Big and SHA-3
[0164] UC is a chronic inflammatory disease characterized by the infiltration of a large number of inflammatory cells in the colon mucosa. Patients often present with abdominal pain, diarrhea, bloody stools with mucus and pus, and tenesmus. Currently, there are many methods for preparing UC model animals, mainly including chemical induction, adoptive transfer, CD4 +T lymphocytes, gene knockout and transgenic, etc. Among them, chemical induction is the most widely used because of its advantages such as simple operation and low cost. Commonly used chemical inducers include DSS, acetic acid, 2,4,6-trinitrobenzenesulfonic acid and oxazolone. Compared with other inducers, the symptoms and colon pathological characteristics of colitis model mice established after DSS induction are most similar to human UC. In addition, this model also has the advantages of high success rate, good reproducibility and uniform distal colon lesions. DSS is a synthetic heparin polysaccharide with anticoagulant properties. It has obvious cytotoxicity to intestinal epithelial cells present in the basal crypts, destroying the integrity of the intestinal mucosal barrier, thereby causing intestinal contents (such as bacteria and their metabolites) to enter and penetrate the internal mucus layer, activating immune cells and inflammatory cells in the intestinal lamina propria. The activated immune cells and inflammatory cells cause intestinal inflammatory reactions by releasing a large number of proinflammatory factors, chemokines, adhesion molecules and reactive oxygen species. In summary, the present application used a DSS-induced colitis model in mice to investigate the inhibitory effect of Big on colitis in mice.
[0165] Experimental materials and reagents
[0166] The drugs used were prepared according to the above Examples 1-6, codenamed Big; DSS (MW 36,000-50,000) was purchased from MP Biomedicals, USA; 5-aminosalicylic acid (5-ASA) was purchased from Aifa Pharmaceuticals, France; and ELISA kits were purchased from Dakoway Biotech Co., Ltd.
[0167] Experimental animals
[0168] Female C57BL / 6 mice, 6-8 weeks old, weighing 18-20 g, were purchased from Jiangsu Jicui Pharmaceutical Technology Co., Ltd. [Production License No.: SCXK (Su) 2018-0008]. The animals were fed and watered freely and were kept in an environment with a room temperature of 22±2°C and a humidity of 45±10%. After 7 days of adaptive feeding, they were used for subsequent experiments.
[0169] Experimental methods
[0170] Establishment of mouse colitis model and grouping and drug administration
[0171] Intraperitoneal injection of Big for the treatment of acute colitis: Female C57BL / 6J mice, 6-8 weeks old, weighing 18-20g, were randomly divided into normal group, model group, Big (0.01mg / kg, 0.1mg / kg, 1mg / kg) group and positive control drug 5-ASA (200mg / kg) group according to body weight, with 6 mice in each group. Except for the normal group, mice in other groups were given 2.5% DSS solution for 7 consecutive days, and then changed to single distilled water for free drinking for 3 days. The day of modeling was recorded as day 1, and Big was injected intraperitoneally and 5-ASA was given by gavage once a day for 9 consecutive days, with a dosing volume of 0.1mL / 10g; mice in the normal group and DSS group were given an equal volume of solvent (0.5% CMC-Na solution). The body weight and disease activity index score of mice were observed during the modeling process. After the modeling, the colon was separated and the length was measured. The effect of Big on the expression of inflammatory factors in the colon tissue of DSS-induced acute colitis mice was detected by ELISA.
[0172] Gavage of Big for acute colitis: Female C57BL / 6J mice, 6-8 weeks old, weighing 18-20g, were randomly divided into normal group, model group, Big (0.1mg / kg, 1mg / kg) group and positive control drug 5-ASA (200mg / kg) group according to body weight, with 6 mice in each group. Except for the normal group, mice in other groups were given 2.5% DSS solution for 7 consecutive days, and then switched to single distilled water for free drinking for 3 days. The day of modeling was recorded as day 1, and Big and 5-ASA were gavaged once a day for 9 consecutive days, with a dosing volume of 0.1mL / 10g; mice in the normal group and DSS group were given an equal volume of solvent (0.5% CMC-Na solution). The body weight and disease activity index score of mice were observed during the modeling process. After the modeling, the colon was separated and the length was measured. The effect of Big on the expression of inflammatory factors in the colon tissue of DSS-induced acute colitis mice was detected by ELISA.
[0173] Treatment of acute colitis by intragastric administration of SHA-3, an effective part of the extract of Inula japonica: Female C57BL / 6J mice, 6-8 weeks old, weighing 18-20g, were randomly divided into a normal group, a model group, a SHA-3 (0.1, 1 mg / kg) group, and a positive control drug 5-ASA (200 mg / kg) group according to their body weight, with 6 mice in each group. Except for the normal group, mice in the other groups were given 2.5% DSS solution for 7 consecutive days, and then switched to single distilled water for free drinking for 3 days. The day of modeling was recorded as day 1, and SHA-3 and 5-ASA were given by intragastric administration once a day for 9 consecutive days, with a dosing volume of 0.1 mL / 10 g; mice in the normal group and DSS group were given an equal volume of solvent (0.5% CMC-Na solution). The body weight and disease activity index score of the mice were observed during the modeling process. After the modeling, the colon was separated and the length was measured. The effect of SHA-3 on the expression of inflammatory factors in the colon tissue of DSS-induced acute colitis mice was detected by ELISA.
[0174] Disease Activity Index Score
[0175] The weight, diarrhea and occult blood of mice were observed and recorded every day, and the disease activity index (DAI) was scored. DAI = (weight score + stool characteristics score + stool bleeding score / 3). The specific scoring criteria are as follows:
[0176] Table 9 Disease Activity Index Scoring Criteria
[0177] Fraction Weight loss (%) Stool characteristics Blood in the stool 0 none normal Negative 1 1-5 - - 2 6-10 Soft Positive 3 11-15 - - 4 >15 diarrhea Visible bleeding
[0178] Fecal occult blood determination: Collect mouse feces and place them in a 24-well culture plate. Add equal volumes of o-toluidine, glacial acetic acid and 3% hydrogen peroxide solution. If it turns blue-brown within 2 minutes, it is judged as positive.
[0179] Specimen collection
[0180] One hour after the last administration, blood was collected from the fundus venous plexus, left at room temperature for 2 hours, centrifuged at 3500rpm and 4℃ for 15-20min, serum was separated, and stored at -20℃ or -80℃. After blood collection, the mice were killed, the abdominal cavity was carefully opened, the colon was taken 1cm away from the anus, the length was measured, the morphological changes were observed, and photos were taken. Subsequently, it was rinsed with pre-cooled PBS solution, 0.4cm of colon tissue was measured from the distal end, fixed in 4% formaldehyde neutral buffer, and the remaining colon was stored in liquid nitrogen for pathological examination.
[0181] ELISA to detect inflammatory factors
[0182] Take an appropriate amount of colon tissue (about 20.0 mg), record the specific weight and place it in a 2mL EP tube. Pipette 1×PBS 9 times the weight of colon tissue into the EP tube and put it into an ultrasonic tissue grinder for grinding. Centrifuge (3000rpm, 4℃, 20min), take the supernatant to obtain 10% colon tissue homogenate. Dilute 10 times when using. Strictly add reagents step by step according to the method described in the ELISA kit instructions, and measure the absorbance at a wavelength of 450nm.
[0183] Statistics
[0184] All data are presented as means±SEM, and the statistical differences among the groups were analyzed using one-way ANONA and t-test in SPSS software. P values less than 0.05 were considered to be significantly different.
[0185] Effects of intraperitoneal injection of Big on ulcerative colitis in mice
[0186] Effects on DAI scores of mice
[0187] The mice in the Normal group were active, had normal bowel movements, and slowly gained weight; the mice given DSS developed loose stools and semi-formed non-stick anal stools as the experimental days progressed, their activity levels decreased, and their weight was significantly reduced. The disease activity index was evaluated by observing the weight loss, stool characteristics, and blood in the stool of the mice daily. As shown in Table 10, compared with the DSS group, the compound Big 1 mg / kg significantly reduced the DAI score increase caused by DSS, and was significantly stronger than the positive control 5-aminosalicylic acid.
[0188] Table 10 DAI scores
[0189]
[0190] Note: Compared with the Normal group ## P<0.01; compared with DSS group * P < 0.05; ** P<0.01.
[0191] Effects on colon length in mice
[0192] As shown in Table 11, the colon length of mice in the DSS group was significantly shortened compared with that in the Normal group. Intraperitoneal injection of compound Big (1 mg / kg) significantly inhibited the shortening of the colon length of mice, and was significantly stronger than the positive control 5-aminosalicylic acid.
[0193] Table 11. Colon length
[0194]
[0195]
[0196] Note: Compared with the Normal group ## P<0.01; compared with DSS group ** P<0.01.
[0197] Effects on inflammatory factors IL-1β and IL-6 in mouse colon
[0198] As shown in Table 12, compared with the mice in the Normal group, the IL-1β and IL-6 in the colon of the mice in the DSS group increased significantly. Intraperitoneal administration of the compound Big (1 mg / kg) significantly inhibited the shortening of the colon length of the mice, and was significantly stronger than the positive control 5-aminosalicylic acid.
[0199] Table 12. Activity of IL-1β and IL-6 in colon tissue
[0200] Group Number of cases IL-1β (ng / mL) IL-6 (ng / mL) Normal 6 0.90±0.05 0.17±0.02 DSS 6 <![CDATA[3.49±0.14 ## ]]> <![CDATA[1.09±0.11 ## ]]> Big (0.01 mg / kg) 6 <![CDATA[2.16±0.12 ** ]]> <![CDATA[0.44±0.07 ** ]]> Big (0.1 mg / kg) 6 <![CDATA[1.63±0.09 ** ]]> <![CDATA[0.47±0.03 ** ]]> Big (1mg / kg) 6 <![CDATA[1.88±0.09 ** ]]> <![CDATA[0.33±0.02 ** ]]> 5-ASA (200 mg / kg) 6 <![CDATA[2.02±0.07 ** ]]> <![CDATA[0.52±0.03 ** ]]>
[0201] Note: Compared with the Normal group ## P<0.01; compared with DSS group * P < 0.5 and ** P<0.01.
[0202] Effects of oral administration of Big on ulcerative colitis in mice
[0203] Effects on DAI scores of mice
[0204] The mice in the Normal group were active, had normal bowel movements, and slowly gained weight; the mice given DSS developed loose stools and semi-formed non-stick anal stools as the experimental days progressed, their activity levels decreased, and their weight was significantly reduced. The disease activity index was evaluated by observing the weight loss, stool characteristics, and blood in the stool of the mice daily. As shown in Table 13, compared with the DSS group, the compound Big 1 mg / kg significantly reduced the DAI score increase caused by DSS, and was significantly stronger than the positive control 5-aminosalicylic acid.
[0205] Table 13. DAI scores
[0206]
[0207]
[0208] Note: Compared with the Normal group ## P<0.01; compared with DSS group * P < 0.05; ** P<0.01.
[0209] Effects on colon length in mice
[0210] As shown in Table 14, the colon length of mice in the DSS group was significantly shortened compared with that of mice in the Normal group. Intragastric administration of compound Big (1 mg / kg) significantly inhibited the shortening of the colon length of mice, and was significantly stronger than the positive control 5-aminosalicylic acid.
[0211] Table 14. Colon length
[0212] Group Number Length (cm) Normal 6 7.35±0.10 DSS 6 <![CDATA[5.75±0.28 ## ]]> Big (0.1 mg / kg) 6 <![CDATA[6.28±0.33 * ]]> Big (1mg / kg) 6 <![CDATA[6.57±0.26 ** ]]> 5-ASA (200 mg / kg) 6 <![CDATA[6.15±0.18 ** ]]>
[0213] Note: Compared with the Normal group ## P<0.01; compared with DSS group ** P<0.01.
[0214] Effect of oral administration of SHA-3, the effective fraction of Inula japonica extract, on DAI score in mice with ulcerative colitis
[0215] The mice in the Normal group were active, had normal bowel movements, and slowly gained weight; the mice given DSS developed loose stools and semi-formed non-stick anal stools as the experimental days progressed, their activity levels decreased, and their weight was significantly reduced. The disease activity index was evaluated by observing the weight loss, stool characteristics, and blood in the stool of the mice daily. As shown in Table 15, compared with the DSS group, SHA-3 (1 mg / kg) significantly reduced the DAI score increase caused by DSS in colitis, and was significantly stronger than the positive control 5-aminosalicylic acid.
[0216] Table 15. DAI scores
[0217]
[0218]
[0219] Note: Compared with the Normal group ## P<0.01; compared with DSS group * P<0.05,; ** P<0.01.
[0220] Effect on colon length
[0221] As shown in Table 16, the colon length of mice in the DSS group was significantly shortened compared with that in the Normal group. Intragastric administration of SHA-3 (1 mg / kg) significantly inhibited the shortening of the colon length of mice, and was significantly stronger than the positive control 5-aminosalicylic acid.
[0222] Table 16. Colon length
[0223] Group Number Length (cm) Normal 6 7.35±0.11 DSS 6 <![CDATA[5.75±0.28 ## ]]> SHA-3 (0.1 mg / kg) 6 <![CDATA[6.45±0.16 * ]]> SHA-3 (1mg / kg) 6 <![CDATA[6.57±0.25 ** <!-- 20 -->]]> 5-ASA (200 mg / kg) 6 <![CDATA[6.15±0.18 ** ]]>
[0224] Note: Compared with the Normal group## P<0.01; compared with DSS group ** P<0.01.
[0225] Embodiment 17
[0226] Compound Big's Anti-allergic Asthma Test
[0227] Experimental reagents
[0228] The drugs used were prepared according to the above Examples 1-6, code-named Big; house dust mite (HDM) was purchased from Greer, USA; physiological saline was purchased from Sewell; dexamethasone (Dex) was purchased from Sigma, USA; isoflurane was purchased from Nanjing Bingtuo Biotechnology; eosinophil counting solution was purchased from Shanghai Yuanye Biotechnology; acetyl-β-methylcholine chloride and ELISA kits were purchased from Formase Biotechnology Co., Ltd.
[0229] Experimental animals
[0230] Male BALB / C mice, 6-8 weeks old, weighing 18-20 g, were purchased from Jiangsu Jicui Pharmaceutical Technology Co., Ltd. [Production License No.: SCXK (Su) 2018-0008]. The animals were allowed to eat and drink freely and were kept in an environment with a room temperature of 22 ± 2 °C and a humidity of 45 ± 10%. After 7 days of adaptive feeding, they were used for subsequent experiments.
[0231] Experimental methods
[0232] Establishment of allergic asthma model in mice and group-based drug administration
[0233] Intragastric administration of Big to treat allergic asthma in mice: Male BALB / C mice, 6-8 weeks old, weighing 18-20 g, were randomly divided into a normal group (Normal), a model group (HDM), a Big (doses of 0.1 mg / kg and 1 mg / kg, respectively) group, and a positive control drug dexamethasone (Dex, 5 mg / kg) group according to their body weight, with 8 mice in each group. The modeling method was that on days 0, 7, and 14 after adaptive feeding, group C (blank control) was intraperitoneally injected with 100ul of saline, and the other groups were intraperitoneally injected with 100ul of HDM (0.5mg / ml). From days 21 to 23, group C was intranasally injected with 10ul of saline, and the other groups were intranasally injected with 10ul of HDM (2.5mg / ml) after inhalation of isoflurane for mild anesthesia. The drug administration method was that from days 17 to 23, group C was intragastrically injected with 100ul of saline, the positive group was intraperitoneally injected with 100ul of positive drug dexamethasone (Dex, 0.67mg / kg), and the experimental group was intragastrically injected with 100ul of Big (0.1mg / kg, 1mg / kg). After 24 hours, an enhanced expiratory interval (Penh) test was performed, mouse serum and lung tissue were separated, and the effect of Big on the expression of inflammatory factors in mouse serum and lung tissue was further detected by ELISA.
[0234] Enhanced expiratory interval (Penh) test: Three mice were randomly selected from each group on D24 for enhanced respiratory interval (Penh) test. The mice were placed in a standard body chamber for spontaneous breathing, and the chamber was connected to a dehumidification pump. 500ul PBS, 6.25mg / ml, 6.25mg / ml, 12.5mg / ml, and 25.0mg / ml of acetyl-β-methylcholine chloride were atomized into the chamber for 1 minute. After each atomization, the Penh value of the mice under the cumulative concentration stimulation of 0, 6.25mg / ml, 12.5mg / ml, and 25.0mg / ml was recorded within 5 minutes.
[0235] Eosinophil counting: Separate mouse whole blood, take 20ul whole blood and dissolve it in 380ul eosinophil counting solution, mix well, let it stand for five minutes, and count the cells under a microscope.
[0236] ELISA detection of inflammatory factor content: After separating the whole blood of mice, centrifuge it at 3500rpm and 4℃ for 15min, take the supernatant, and use ELISA to detect the IgE content in the serum; after separating the mouse lung tissue, add PBS according to the ratio of 1mg lung tissue: 20ul PBS and grind it thoroughly, centrifuge it at 12000rpm and 4℃ for 10min, take the supernatant, and use ELISA kit to detect the IL-4 content in the lung tissue grinding fluid.
[0237] Take an appropriate amount of colon tissue (about 20.0 mg), record the specific weight and place it in a 2mL EP tube. Pipette 1×PBS 9 times the weight of colon tissue into the EP tube and put it into an ultrasonic tissue grinder for grinding. Centrifuge (3000rpm, 4℃, 20min), take the supernatant to obtain 10% colon tissue homogenate. Dilute 10 times when using. Strictly add reagents step by step according to the method described in the ELISA kit instructions, and measure the absorbance at a wavelength of 450nm.
[0238] Statistics
[0239] All data are presented as means±SEM, and the statistical differences among the groups were analyzed using one-way ANONA and t-test in SPSS software. P values less than 0.05 were considered to be significantly different.
[0240] As shown in Table 17, compared with the mice in the Normal group, the airway resistance of the mice in the HDM group increased significantly. Intragastric administration of the compound Big (0.1 mg / kg and 1 mg / kg) inhibited the increase of airway resistance in mice.
[0241] Table 17. Penh values of Big mice given oral administration
[0242]
[0243]
[0244] As shown in Table 18, compared with the mice in the Normal group, the expression of eosinophils (EOS) in the whole blood of the mice in the HDM group was significantly increased. Intragastric administration of compound Big (0.1 mg / kg and 1 mg / kg) dose-dependently inhibited the increase of EOS expression in the whole blood of mice.
[0245] Table 18. EOS expression in whole blood of Big mice given intragastric administration
[0246] Group Number EOS Normal 5 <![CDATA[(1.09±0.8)×10 7 ]]> HDM 5 <![CDATA[(1.6±0.245)×10 8 ]]> Big (0.1 mg / kg) 5 <![CDATA[(1.28±0.109)×10 8 *]]> Big (1mg / kg) 5 <![CDATA[(1.08±0.109)×10 8 **]]> Dex (0.67 mg / kg) 5 <![CDATA[(9.6±0.894)×10 7 **]]>
[0247] Note: *p<0.05; **p<0.01 (compared with HDM group)
[0248] As shown in Table 19, compared with the mice in the Normal group, the expression of inflammatory factors IgE and IL-4 proteins in the serum and lungs of the HDM group mice was significantly increased. Oral administration of compound Big (0.1 mg / kg and 1 mg / kg) dose-dependently inhibited the increase of inflammatory factors IgE and IL-4 protein expression in the serum and lungs of mice.
[0249] Table 19. Expression of inflammatory factors IgE and IL-4 in serum and lung of Big mice given oral administration
[0250]
[0251] Note: *p<0.05; **p<0.01 (compared with HDM group)
[0252] Embodiment 18
[0253] Anti-acute gastritis test of compound Big
[0254] Experimental reagents
[0255] The drugs used were prepared according to the above Examples 1-6, codenamed Big; concentrated hydrochloric acid (HCl) and ethanol (Ethanol) were purchased from Xilong Chemical Company; dexamethasone (Dex) was purchased from Sigma Company, USA; and ELISA kits were purchased from Dakoway Biotechnology Co., Ltd.
[0256] Experimental animals
[0257] Male C57BL / 6 mice, 6-8 weeks old, weighing 18-20 g, were purchased from Jiangsu Jicui Pharmaceutical Technology Co., Ltd. [Production License No.: SCXK (Su) 2018-0008]. The animals were fed and watered freely and were kept in an environment with a room temperature of 22±2°C and a humidity of 45±10%. After 7 days of adaptive feeding, they were used for subsequent experiments.
[0258] Experimental methods
[0259] Establishment of acute gastritis model in mice and grouped drug administration
[0260] Oral administration of Big to prevent gastritis in mice: Male C57BL / 6J mice, 6-8 weeks old, weighing 18-20g, were randomly divided into a normal group (Normal), a model group (HCl / Ethanol), a Big (doses of 0.1mg / kg, 1mg / kg) group, and a positive control drug dexamethasone (Dex, 5mg / kg) group according to their weight, with 6 mice in each group. Three days before modeling, Big (0.1mg / kg, 1mg / kg) and positive drug dexamethasone (Dex, 5mg / kg) were administered orally every day. On the third day, 300μL of 150mMHCl / 60% Ethanol was administered orally half an hour after administration. One hour later, the mouse stomach was carefully separated, and the effect of Big on the expression of inflammatory factors in the mouse stomach was further detected by qPCR (Table 16).
[0261] Statistics
[0262] All data are presented as means±SEM, and the statistical differences among the groups were analyzed using one-way ANONA and t-test in SPSS software. P values less than 0.05 were considered to be significantly different.
[0263] Effects of intragastric administration of Big on acute gastritis in mice
[0264] As shown in Table 17, compared with the mice in the Normal group, the mRNA expression of inflammatory factors Il1 and Il6 in the stomach of mice in the HCl / Ethanol group was significantly increased. Preventive administration of compound Big (0.1 mg / kg and 1 mg / kg) by intragastric administration dose-dependently inhibited the increase of Il1 and Il6 mRNA expression in the stomach of mice.
[0265] Table 20. Expression of inflammatory factors Il1 and Il6 mRNA in the stomach of Big mice given preventive drugs by oral gavage
[0266]
[0267] Note: *p<0.05; **p<0.01 (compared with HCl / Ethanol group)
[0268] Embodiment 19
[0269] Activity determination of compound Big in treating acute kidney injury
[0270] Experimental methods: An acute renal injury model was established in C57BL / 6J mice by intraperitoneal injection of 250 mg / kg folic acid (FA) for 48 hours; Big was orally administered to mice at a concentration of 1 mg / kg to investigate the therapeutic effect of Big on renal injury.
[0271] As shown in Table 21: After oral administration of 1 mg / kg concentration of Big to mice, the transcription levels of kidney injury and inflammation-related marker genes were significantly decreased compared with the acute mouse renal injury model group; the above results indicate that Big has a good effect in treating acute kidney injury.
[0272] Table 21. Relative expression levels of kidney injury genes and inflammatory genes in oral Big mice
[0273]
[0274] Note: Compared with FA group ** P<0.01.
[0275] Embodiment 20
[0276] Activity determination of compound Big in treating atopic dermatitis
[0277] Experimental reagents
[0278] The drugs used were prepared according to the above Examples 1-6, code-named Big; white vaseline (Macklin, V820408), light liquid paraffin (Sigma-Aldrich, 8002-74-2), glyceryl monostearate (Shanghai Yuanye Biotechnology Co., Ltd., S30304), Tween 80 (Macklin, T818929), propylene glycol (Jiangxi Yipsheng Pharmaceutical Co., Ltd., 20231201), ethylparaben (Sigma-Aldrich, PHR1011) and hexadecanol (Jiangxi Alpha Hi-Tech Pharmaceutical Co., Ltd., 20230601).
[0279] Experimental animals
[0280] Male C57BL / 6 mice, 6-8 weeks old, weighing 18-20 g, a total of 36 mice, were purchased from Jiangsu Jicui Pharmaceutical Technology Co., Ltd. [Production License No.: SCXK (Su) 2018-0008]. The animals were fed and watered freely and were kept in a barrier environment with a room temperature of 22±2°C and a humidity of 45±10%. After 7 days of adaptive feeding, they were used for subsequent experiments.
[0281] Experimental methods
[0282] Preparation of blank ointment:
[0283] (1) Preparation of oil phase: Weigh white vaseline (7.5 g), light liquid paraffin (2.0 g), glyceryl monostearate (2.0 g), ethylparaben (0.05 g) and hexadecanol (5.0 g), heat to 65° C., stir to dissolve, slowly add to the dissolved raw material drug (ensuring that the content of the raw material drug accounts for 1% or 0.1% of the total system mass fraction), continue stirring, mix evenly, and set aside;
[0284] (2) Preparation of aqueous phase: Weigh purified water (25.4 g for 0.1% ointment, 24.95 g for 1% ointment) and Tween 80 (4.0 g), heat to 70°C, stir and dissolve for later use;
[0285] (3) Emulsification: Slowly add the water phase into the oil phase, maintain 65°C, homogenize, and continue stirring for 30 min;
[0286] (4) Cool down, stop heating, continue stirring, gradually reduce to room temperature and cool into paste, and fill.
[0287] Preparation of 0.1% 1% Big Ointment and 1% Dexamethasone Ointment
[0288] Weigh 0.05g and 0.5g of compound Big and 0.5g of dexamethasone respectively, dissolve in a small amount of propylene glycol, and place in the above-condensed blank ointment base, finally add water to 50g, and grind with a mortar to obtain 0.1% and 1% compound Big ointment and 1% dexamethasone ointment.
[0289] Establishment of MC903-induced AD mouse model and drug administration
[0290] Establishment and administration of mouse ear AD model: 36 mice were randomly divided into a normal group (Normal), a model group (MC903), 0.1%, 1% Big, and dexamethasone (Dex), with 6 mice in each group. Except for the normal group, AD models were established in all other groups: 20 μL of MC903 solution was applied to each ear of the mouse once a day for 14 consecutive days to induce atopic dermatitis model in mice. Seven days after modeling, 20 mg of 0.1%, 1% Big and dexamethasone ointment were evenly applied to the corresponding mice every day, and blank ointment was applied to the model and normal mice every day. The changes in the thickness of the mouse ears were measured every 2 days with an electronic vernier caliper before modeling and after administration. Photos of the mouse skin lesions were taken 24 hours after the completion of the 14th day, and the mouse skin lesions and blood samples were collected.
[0291] Lesion severity scoring: The following criteria were used to score the severity of skin lesions in mice every day, mainly including 4 symptoms, namely 1) erythema / hemorrhage; 2) dryness; 3) exfoliation / erosion; 4) edema. Each symptom was scored 0-3 points depending on the severity of the lesions, with 0 points for no symptoms, 1 point for mild, 2 points for moderate, and 3 points for severe. The sum of all symptom scores is the severity of the lesions. The higher the score, the more severe the lesions. The maximum score is no more than 12 points, and the data are statistically analyzed. On the 14th day of the experiment, the AD-like lesions such as erythema, edema, dryness, exudation and scabs were compared among the groups, and photographed and recorded with a digital camera.
[0292] Experimental results: Compared with the normal group of mice, the ear skin lesions of the model group mice showed obvious AD-like skin lesions such as erythema, scaling, scabs and edema. However, after the application of 0.1% and 1% compound Big ointment, the above symptoms of the mice were significantly alleviated.
[0293] As shown in Table 22, as the modeling time prolonged, the ear thickness of the AD group (MC903) mice increased significantly, but the thickness increase rate of the compound Big administration group was significantly lower than that of the AD group. On the last day of the experiment, the ear thickness of the AD group mice increased by 2.5 times compared with the baseline value, while the inhibition rates of 0.1% and 1% compound Big ointment were 48% and 58%, respectively. This suggests that compound Big can alleviate the severity of mouse ear lesions.
[0294] Table 22. Compound Big significantly reduces the thickness of the auricle of AD mice
[0295]
[0296] Note: ## p<0.01 (compared with the Normal group); * p<0.05, ** p<0.01, *** p<0.001 (compared with MC903 group).
[0297] As shown in Table 23, compared with normal mice, AD mice developed skin lesion-like symptoms in the ears, manifested as obvious erythema, scaling, scabs and edema, and continuous application of 0.1% and 1% compound Big ointment for 7 days significantly alleviated the skin lesion symptoms of mice, as manifested by a significant decrease in dermatitis scores.
[0298] Table 23. Compound Big significantly down-regulated the ear dermatitis score of AD mice
[0299] Group Dermatitis score Normal 0.00±0.00 MC903 <![CDATA[6.80±1.10 ## ]]> Big (0.1%) <![CDATA[3.00±0.71 *** ]]> Big (1%) <![CDATA[2.40±0.55 *** ]]> Dex (1%) <![CDATA[2.60±0.55 *** ]]>
[0300] Note: ## p<0.01 (compared with the Normal group); *** p<0.001 (compared with MC903 group).
Claims
1. Use of a pseudoguaiacyl sesquiterpene derivative or a pharmaceutically acceptable salt thereof as a NLRP3 inflammasome activation inhibitor in the preparation of a drug for treating NLRP3 inflammasome-related diseases as shown in the following formula I: Where: R1 and R2 together form a double bond; or R1 is hydrogen or deuterium, R2 is and pharmaceutically acceptable salts thereof formed with inorganic or organic acids, including hydrochlorides, fumarates, etc., wherein R4 and R5 are independently selected from hydrogen or C1-C3 alkyl; R3 is H or acyl.
2. The use according to claim 1, characterized in that The pseudoguaiacyl sesquiterpene derivative represented by formula I or a pharmaceutically acceptable salt thereof is selected from any one of the following compounds:
3. The use according to claim 1, characterized in that The NLRP3 inflammasome-related diseases include immune diseases, autoimmune diseases, kidney system-related diseases, gastrointestinal tract-related diseases, respiratory diseases, infectious diseases, and skin diseases.
4. The use according to claim 3, characterized in that The respiratory diseases include acute lung injury, asthma, asbestosis, and silicosis.
5. The use according to claim 3, characterized in that: The kidney system related diseases include chronic kidney disease, oxalate nephropathy and diabetic nephropathy.
6. The use according to claim 3, characterized in that: The gastrointestinal tract related diseases include inflammatory bowel disease and gastritis, and the infectious diseases include inflammatory cytokine storm and sepsis caused by bacterial and viral infections.
7. The use according to claim 3, characterized in that: The skin-related diseases include atopic dermatitis.
8. An effective part of an extract of a plant of the genus Inula, characterized in that: The content of caerulein in the compound shown in formula I accounts for 10%-90% of the mass percentage of the effective part.
9. Use of the effective fraction of the Inula plant extract according to claim 8 in the preparation of a medicament for treating NLRP3 inflammasome-related diseases.
10. A pharmaceutical composition, characterized in that It comprises any one of the pseudoguaiacyl sesquiterpene derivatives shown in formula I in claims 1-2 or a pharmaceutically acceptable salt thereof, or the effective part of the Inula plant extract according to claim 8, and a pharmaceutically acceptable carrier.
11. Use of the pharmaceutical composition according to claim 10 in preparing a drug for treating NLRP3 inflammasome-related diseases.
